Imatinib Krka D.D. (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, blocking their enzymatic activity. This inhibition stops downstream signaling pathways that promote cell proliferation and survival, leading to apoptosis of cancer cells that rely on these kinases.

The exact dosage of Imatinib Krka D.D. is determined by the prescribing clinician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other individual factors. Healthcare providers set the appropriate regimen for each patient.

Safety data for Imatinib in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit outweighs the risk to the fetus or infant. Women of child‑bearing potential should discuss contraception and treatment options with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first targeted BCR‑ABL inhibitor and remains a standard first‑line therapy for chronic phase CML. Newer agents such as dasatinib and nilotinib offer alternative potency and side‑effect profiles, but Imatinib’s long‑term safety data and cost‑effectiveness make it a widely used option.

Imatinib Krka D.D. tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

The medication is taken orally, usually once daily, with a glass of water. It can be swallowed with or without food, but patients should follow the specific instructions provided by their healthcare professional to maintain consistent drug exposure.

Serious risks include severe neutropenia, hepatotoxicity, cardiac failure, pulmonary hypertension, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for blood counts, liver enzymes and cardiac function to detect these complications early.

Imatinib is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with pre‑existing severe cardiac disease, uncontrolled infections, or significant liver impairment, as these conditions may increase the risk of adverse events.